OSLO, Norway--(BUSINESS WIRE)--The human antibody company, Affitech AS, announced today that it has further strengthened its intellectual property (IP) position in the human antibody discovery area through a series of IP cross-licensing and in-licensing deals. The Company’s primary antibody library display patents are known as "Breitling" IP. Originating from the DKFZ (German Cancer Research Center) of Heidelberg, Germany, the Breitling patents cover the use of full-length pIII phage protein as a scaffold in a phagemid vector, and are one of the fundamental group of patents for the phagemid display of antibody, antibody fragments and proteins. Affitech’s new deals include exclusive worldwide in licensing of a sublicensable Diabody IP from Pharmexa (Copenhagen, Denmark) and a non-exclusive worldwide sub-licensable research license of single-chain antibodies (SCA) from Micromet (Munich, Germany). These follow previous cross-licenses of Breitling IP with Dyax's (Cambridge, MA) "Ladner" family of phage display technology patents and XOMA’s (Berkeley, CA) bacterial cell expression (BCE) technology for developing antibody products
